Navigation Links
Epitope in Medical Technology

Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)

... that targets a membrane-proximal (close to the cell surface), small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule on B cells.(4) This epitope is different from the binding sites targeted by other CD20 antibodies ...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

... research and development activities with its L.E.A.P.S.(TM) (Ligand epitope Antigen Presentation System) technology. L.E.A.P.S.(TM) is a novel T-cell ... peptides. The L.E.A.P.S.(TM) constructs containing the antigenic disease epitope linked to a T-cell binding ligand (TCBL) can be manufactured by peptide ...

Genmab A/S - Company Announcement: Recruitment Completed In Ofatumumab CLL Front Line Study

... fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 molecule on the surface of B-cells. Other anti-CD20 antibodies currently available or in development bind to a different epitope on the CD20 molecule. Ofatumumab is being developed to treat CLL, ...

Genmab Reaches Milestone in Ofatumumab Collaboration

... next generation monoclonal antibody that targets a distinct small loop epitope on the CD20 receptor on the surface of B-cells. This epitope is different from the other anti-CD20 antibodies currently available or in ...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

... function of the T lymphocytes that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T cells and by doing so, may modulate the immunologic response that is a key component of the disease. ...

CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas

... data at the annual American Society for Microbiology in Philadelphia, PA. This data demonstrates that vaccines utilizing its L.E.A.P.S.(TM) (Ligand epitope Antigen Presentation System) vaccine technology with specificity for particular Mycobacterium tuberculosis (TB) antigens can elicit immune ...

FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab)

... About Ofatumumab Ofatumumab is an investigational monoclonal antibody that targets a membrane-proximal (close to the cell surface), small loop epitope (a portion of a molecule to which an antibody binds) on the CD20 molecule on B-cells. Ofatumumab also binds to the large loop of the CD20 molecule. ...

Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy

... is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's products offer potential major clinical benefits compared with existing therapies, and ...

Circassia's Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients

... is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's anti-allergy products offer potential major clinical benefits compared with existing therapies, ...

Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment

... nearly 10% of Europeans suffering from the condition. Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. In addition to ToleroMune's potential therapeutic benefits, its state-of-the-art manufacturing processes fit ...

Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology

... Lansdowne Partners, Goldman Sachs and Invesco Perpetual. Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach ...

Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology

... Lansdowne Partners, Goldman Sachs and Invesco Perpetual. Circassia's lead products target allergies utilizing the company's proprietary T-cell epitope desensitization technology, ToleroMune. The company is also developing its ToleroTrans organ anti-rejection technology, which uses a similar approach ...

Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study

... and their physicians." Ofatumumab is an investigational new generation fully human monoclonal antibody that uniquely targets the small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular ...

IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients

... from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes and one universal epitope a source of T-cell help. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using ...

IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients

... from four tumor associated antigens (TAA) including two proprietary native epitopes and seven modified, or analog, epitopes and one universal epitope a source of T-cell help. Tolerance to TAA, which is a failure of the immune system to recognize the cancer as diseased tissue, is broken by using ...

MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus

... function of the T lymphocytes that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T cells and by doing so, may modulate the immunologic response that causes disease. About Type 1 ...

ARIUS to Present at American Association for Cancer Research Annual Meeting

... of our FunctionFIRST(TM) platform to generate novel antibodies with promising anti-cancer properties." Novel antibody ARH460-16-2 recognizes an epitope of CD44 that is highly expressed in liver cancers. Abstract 662, Section 27, Board 15, Sunday, Apr 15, 8AM - 12PM ARH460-16-2, a functional ...

ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting

... IMC-EB10, NC7, and D4-3 (Anti-FLT3 MAb) (#4110 Williams et al. Elucidation of the antagonistic mechanisms of various anti-FLT3 antibodies via binding epitope dissection.) -- IMC-D11 (anti-FGFR3 MAb) (#2080 DiRenzo et al. Neutralizing antibody against FGFR3 shows anti-tumor effects in multiple ...

IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at 2007 ASCO Annual Meeting

... the cancer as diseased tissue, is broken by using these analog epitopes which enhance the potency of the T cell response. PADRE(R), a universal HTL epitope we have licensed from Pharmexa, is also included in the vaccine as an immunostimulant. The phase II EP-2101 study has been ongoing since late 2004. ...

Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy

... indicate therapy of tumors can be achieved with 500 microCi of Y-90 or less. About hPAM4 hPAM4 is a humanized monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancer, but not pancreatitis, normal pancreas or most other normal tissues. Preclinical studies with ...

New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus

... need to be updated. As such they do not provide protection against emerging flu strains, such as seasonal or avian flu. Using a novel proprietary epitope prediction algorithm, PepTcell has successfully identified immunogenic regions of flu virus that have not changed over 60 years, in both human and ...

New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus

... need to be updated. As such they do not provide protection against emerging flu strains, such as seasonal or avian flu. Using a novel proprietary epitope prediction algorithm, PepTcell has successfully identified immunogenic regions of flu virus that have not changed over 60 years, in both human and ...

Pharmexa A/S (DK) - Pharmexa presents data from influenza program

... infection. The vaccine is designed to induce T-cell responses to highly-conserved influenza epitopes that were identified using the proprietary epitope Identification System (EIS®). Pharmexa-Epimmune's approach is unique to the field where most vaccines are designed with the explicit goal of ...
Other Contents
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) ... Global Market Overview" report to their offering. , ... ensure that an individual is who she/he is claiming to ... of a person,s unique physical characteristics, such as fingerprint, hand ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
(Date:2/26/2015)... February 26, 2015 Participants in ... What’s Working? What’s Not? What’s New? ,” will ... programs to achieve strong outcomes for duals-plan members ... happening in the implementation phase of programs for ... made? Which ones need to be implemented in ...
(Date:2/26/2015)... February 26, 2015 The Reproductive Science ... their newly renovated office in Lawrenceville, NJ. ... Center of New Jersey’s physicians, and NJ Top Docs, ... care in the areas of infertility and reproductive medicine. ... excellent success rates and providing current, high quality medical ...
(Date:2/26/2015)... February 26, 2015 Software and ... FDA’s Position and Best Practices for Compliance, **Presented ... Bethesda, MD, http://www.fdanews.com/SoftwareAndCybersecurity , This workshop ... — has been specifically designed to provide attendees ... effectively assure medical device software safety. , In ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 A tummy ... that accomplish two different things—but they can be combined ... a tummy tuck with liposuction, Michigan’s Dr. Pramit Malhotra ... he's seen grow in popularity by 50 percent in ... are more patients seeking to combine the two? First, ...
(Date:2/26/2015)... Deerfield, IL (PRWEB) February 26, 2015 ... present during adolescence and young adulthood. In response ... age group, and in support of National Eating ... and Medicine (SAHM) presents new evidence-based recommendations for ... adolescents and young adults, including a new approach ...
Breaking Medicine News(10 mins):Health News:Upcoming AIS Virtual Conference Will Explain What Is and Is Not Working in Medicare-Medicaid Dual Eligibles Programs 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 2Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 3Health News:FDAnews New Workshop — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, April 14-15 4Health News:Dr. Pramit Malhotra Reports a Rise in Patients Combining Liposuction and Tummy Tuck in Michigan, Citing the “Power LipoTuck” 2Health News:Dr. Pramit Malhotra Reports a Rise in Patients Combining Liposuction and Tummy Tuck in Michigan, Citing the “Power LipoTuck” 3Health News:SAHM: Medical Providers Have Vital Lead Role in Diagnosing, Treating Restrictive Eating Disorders in Adolescents and Young Adults 2Health News:SAHM: Medical Providers Have Vital Lead Role in Diagnosing, Treating Restrictive Eating Disorders in Adolescents and Young Adults 3
Other TagsOther Tags